M. Pharm. Ph.D.
Specialization: Pharmacognosy
Experience:
Research: 3 Years
Academic: 2 Years
Thrust Research Areas:
Natural Product Synthesis, Organic Synthesis, CADD, Alzheimer's Disease Research, Kinases Drug Design
Awards:
• Awarded Travel Bursary by Alzheimer’s Disease International to attend the ADI 2022conference in Oval, London, UK.
• Awarded Senior Research Fellow (SRF) by Council of Scientific and Industrial Research(CSIR) 2019.
• Awarded Junior Research Fellow (JRF) by Department of Science and Technology –Rajasthan 2018.
• Best Prize for poster presentation at Emerging Trends in Drug Discovery, Pharmaceutical Science and Biomedical Research, 17-18th March 2018, Organized by Department of Pharmacy, IGNTU, Amarkantak, MP.
• Awarded a scholarship by Shri Guru Ram RaiInstitute of Technology & Science, Dehradun for outstanding performance inacademics 2008-2009.
Publications:
Publications: 12
Google Scholar link: https://scholar.google.com/citations?hl=en&user=RgUNB6wAAAAJ
ORCiD link: https://orcid.org/my-orcid?orcid=0000-0001-9877-6349
Scopus link: Scopus Author ID: 5719559671
Recent Publications-
Sukanya Sukanya, Aina Bellver-Sanchis, BhanwarSingh Choudhary, Sunil Kumar, Belen Perez, Antón Leandro Martínez Rodríguez,Jose Brea, Carmen Escolano, Christian Griñán-Ferré, Ruchi Malik. Exploring2-Thioxo-1,2,3,4-tetrahydropyrimidines as Dual Acting GSK-3ß/Aß Aggregationinhibitors: Implications for Alzheimer's Disease Treatment. Drug DevelopmentResearch, 2025, 86, e70112. doi: 10.1002/ddr.70112 (Impact factor: 4.2)
Sukanya Sukanya, Aina Bellver-Sanchis, BhanwarSingh Choudhary, Sunil Kumar, Belén Pérez, Antón Leandro Martínez Rodríguez,Jose Brea, Christian Griñán-Ferré, Ruchi Malik. Design, synthesis, andbiological evaluation of tetrahydropyrimidine analogue as GSK-3ß/Aß aggregationinhibitor and anti-Alzheimer’s agent. Bioorganic Chemistry, 2024, 153, 107811.doi: 10.1016/j.bioorg.2024.107811 (Impact factor: 4.7)
Sukanya Sukanya, Bhanwar Singh Choudhary,Pakhuri Mehta, Slawomir Filipek, Ruchi Malik. Identification of CNS compatiblesmall molecules as Glycogen synthase kinase-3ß (GSK-3ß) inhibitors throughstructure-based virtual screening. Medicinal Chemistry Research. 2022,31,1545–1557. doi:10.1007/s00044-022-02912-z (Impact factor: 3.1)
Aina Bellver-Sanchis, Bhanwar Singh Choudhary,Júlia Companys-Alemany, Sukanya Sukanya, Pedro A. ÁvilaLópez, Antón LeandroMartínez Rodríguez, Jose Manuel Brea Floriani, Ruchi Malik, Belén Pérez, MercèPallàs, and Christian Griñán-Ferré. Structure based virtual screening, in vitroand in vivo analysis revealed novel potent methyltransferase G9a inhibitors asprospective anti-Alzheimer’s agents. ChemMedChem. 2022, 17(13), e202200002doi:10.1002/cmdc.202200002 (Impact factor: 3.4)
Bhanwar Singh Choudhary, Sukanya, PakhuriMehta, Stephane Bach, Sandrine Ruchaud, Thomas Robert, Beatrice Josselin,Slawomir Filipek, Ruchi Malik. Discovery of thiazolidin-4-one analogue asSelective GSK-3ß inhibitor through structure-based virtual screening.Bioorganic and Medicinal Chemistry Letters, 2021, 52, 128375.doi:10.1016/j.bmcl.2021.128375 (Impact factor: 2.2)
Sukanya, Prajapati, B.G., Patil, V. M.,Choudhary, B. S. (2023) Dual specificity tyrosine phosphorylation regulatedkinase1A (DYRK1A) inhibitors: the quest for a disease-modifying treatment forAlzheimer’s Disease. In Kumar, D., Patil, V. M., Wu, D., Thorat N. (eds)Deciphering Drug Targets for Alzheimer’s Disease. Springer, Singapore. Doi:10.1007/978-981-99-2657-2_4.
Conferences attended: 07
Paper Presentations: 05
Contact details:
E-mail: sukanya@bncp.ac.in